Table 3.
Organ failure | No organ failure | P -value | |
---|---|---|---|
(n = 55) | (n = 11) | ||
Age, years | 59 (45 to 76) | 69 (45 to 92) | 0.429 |
Gender, M/F, n | 34/21 | 4/7 | 0.182 |
BMI, kg/m2 | 25.7 ± 3.8 | 26.2 ± 4.4 | 0.748 |
Body weight, kg | 68.3 ± 12.2 | 65.7 ± 10.9 | 0.545 |
Etiology, alcohol/biliary/ERCP/others | 21/30/1/3 | 4/7/0/0 | 0.815 |
Leukocytes, ×109/l | 13.1 ± 6.6 | 9.1 ± 4.6 | 0.058 |
Hemoglobin, g/dl | 10.4 ± 2.3 | 10.3 ± 1.5 | 0.936 |
Platelets, ×109/l | 138 (72 to 229) | 139.5 (58.5 to 247.3) | 0.935 |
BUN, mg/dl | 23 (12.5 to 41.5) | 12 (7 to 22) | 0.023 |
Serum Creatinine, mg/dl | 1.5 (0.9 to 3.2) | 0.7 (0.6 to 0.9) | <0.001 |
Bilirubin, mg/dl | 1.6 (1.1 to 5.4) | 1.5 (1 to 4) | 0.642 |
INR | 1.2 (1.1 to 1.5) | 1.05 (1 to 1.13) | 0.002 |
Ransons score | 5.5 (4 to 7) | 4 (3 to 4) | 0.001 |
APACHE II score | 18 (11 to 25.5) | 14 (10 to 15) | 0.028 |
SOFA score | 6 (4.3 to 9.8) | 3 (2 to 5) | 0.005 |
Modified Marshall score | 5 (3 to 7.25) | 1 (0 to 1) | <0.001 |
Infected necrosis, n | 18 (32.7%) | 0 (0%) | 0.028 |
Cholesterol, mg/dl | 117 (83 to 142) | 151 (109 to 172) | 0.046 |
Triglyceride, mg/dl | 148 (105 to 285) | 132 (92 to 167) | 0.242 |
HDL, mg/dl | 15 (6 to 22) | 24 (19 to 33) | 0.010 |
LDL, mg/dl | 56 (37 to 75) | 82 (65 to 100) | 0.005 |
APO A-I, mg/dl | 54 (41 to 74) | 78 (55 to 96) | 0.020 |
IL-6, pg/ml | 129 (54 to 251.5) | 29 (10.4 to 101.5) | 0.005 |
TNF-α, pg/ml | 10.8 (4.7 to 23) | 2.9 (1.1 to 3.7) | 0.001 |
CRP, mg/l | 190.6 ± 108.9 | 111.0 ± 90.4 | 0.027 |
Hospital mortality | 13 (23.6%) | 0 (0%) | 0.104 |
ICU mortality | 9 (16.4%) | 0 (0%) | 0.337 |
28-day mortality | 11 (20%) | 0 (0%) | 0.188 |
ICU stay, days | 8 (5 to 14.5) | 5 (5 to 11) | 0.510 |
Results are presented as mean ± SD, or median (IQR) unless otherwise stated. M, male; F, female; BMI, body mass index; ERCP, endoscopic retrograde cholangiopancreagraphy; BUN, blood urea nitrogen; INR, international normalized ratio; APACHE, acute physiology and chronic health evaluation; SOFA, sequential organ failure assessment; HDL, high-density lipoprotein; LDL, low-density lipoprotein; APO A-I, apolipoprotein A-I; CRP C-reactive protein.